Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) (AC4115321)

9 października 2017 zaktualizowane przez: GlaxoSmithKline
The purpose of this study is to further characterize the dose response of GSK573719 at doses of 15.6 micrograms (mcg) to 125 mcg once daily in patients with chronic obstructive pulmonary disease (COPD). Treatment with doses of GSK573719 dosed twice daily will also be included to further evaluate dosing frequency. Treatment with tiotropium (18 mcg) once daily via the Handihaler will be included as an active control. A placebo treatment will be included in order to evaluate absolute treatment effect of the different doses of GSK573719.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

Inhaled bronchodilators, such as beta 2 agonists and anticholinergics, and inhaled corticosteroids are the mainstays of therapy in patients diagnosed with COPD. Anticholinergic bronchodilators or long acting muscarinic receptor antagonists function by blocking endogenous airway smooth muscle cholinergic tone. Treatment with anticholinergics has been shown to significantly improve forced expiratory volume in 1 second (FEV1), resting and dynamic lung hyperinflation, symptoms, and exercise capacity in patients with COPD. Currently tiotropium is the only approved long acting muscarinic antagonist available for treatment of COPD.

This is a multicenter, randomized, double-blind, placebo controlled, three way crossover, incomplete block study to evaluate 4 doses of GSK573719 inhaled once daily and 2 doses of GSK573719 inhaled twice daily over 7 days in patients with COPD. Tiotropium will be included as an open label active comparator. A placebo treatment will be included to evaluate treatment effect of each GSK573719 dose. Pharmacokinetic profiles of GSK573719 will also be determined. Each eligible subject will receive a sequence of 3 of 8 potential treatments for a total of 3 treatment periods per subject. There will be 7 clinic visits, during three of which 24 hour serial spirometry will be performed. The total duration of subject participation is approximately 9 weeks.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

163

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Stany Zjednoczone
    • California
      • Costa Mesa, California, Stany Zjednoczone, 92626
        • GSK Investigational Site
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30342
        • GSK Investigational Site
      • Duluth, Georgia, Stany Zjednoczone, 30096
        • GSK Investigational Site
    • Minnesota
      • Edina, Minnesota, Stany Zjednoczone, 55438
        • GSK Investigational Site
    • North Carolina
      • Charlotte, North Carolina, Stany Zjednoczone, 28207
        • GSK Investigational Site
      • Raleigh, North Carolina, Stany Zjednoczone, 27607
        • GSK Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73103
        • GSK Investigational Site
    • South Carolina
      • Easley, South Carolina, Stany Zjednoczone, 29640
        • GSK Investigational Site
      • Gaffney, South Carolina, Stany Zjednoczone, 29340
        • GSK Investigational Site
      • Greenville, South Carolina, Stany Zjednoczone, 29615
        • GSK Investigational Site
      • Orangeburg, South Carolina, Stany Zjednoczone, 29118
        • GSK Investigational Site
      • Spartanburg, South Carolina, Stany Zjednoczone, 29303
        • GSK Investigational Site
      • Union, South Carolina, Stany Zjednoczone, 29379
        • GSK Investigational Site

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

40 lat do 80 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Outpatient
  • A signed and dated written informed consent prior to study participation.
  • Male or female adults.
  • 40 to 80 years of age at Visit 1
  • Diagnosis of COPD
  • Current or former cigarette smokers with a history of cigarette smoking of greater than or equal to 10 pack-years
  • Post-albuterol forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC)<0.70 and post albuterol FEV1 of greater than or equal to 35% and less than or equal to 70% of predicted normal values

Exclusion Criteria:

  • Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • A current diagnosis of asthma
  • Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer
  • Other significant respiratory conditions in addition to COPD
  • Other diseases that are uncontrolled including cancer in remission for less than 5 years
  • Chest x-ray or CT scan with clinically significant abnormalities not believed to be due to the presence of COPD
  • Hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate
  • A medical condition that contraindicates study participation or use of an inhaled anticholinergic
  • Hospitalization for COPD or pneumonia within 12 weeks of Visit 1
  • Any previous lung resection surgery
  • A body mass index (BMI) value of >35 kilogram (kg)/meter squared (m2)
  • An abnormal and significant electrocardiogram finding at Visit 1
  • Significantly abnormal finding from clinical chemistry or haematology tests at Visit 1.
  • A positive Hepatitis B surface antigen or positive Hepatitis C antibody
  • Medically unable to withhold albuterol (salbutamol) for the 6 hour period prior to study visits
  • Use of depot corticosteroids within 12 weeks of Visit 1
  • Use of oral or parenteral corticosteroids or antibiotics for lower respiratory tract infection within 6 weeks of Visit 1
  • Use of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) product if LABA/ICS therapy is discontinued within 30 days of Visit 1
  • Use of ICS at a dose of >1000mcg/day of fluticasone propionate or equivalent within 30 days of Visit 1
  • Initiation or discontinuation of ICS within 30 days of Visit 1
  • Use of tiotropium or phosphodiesterase 4 inhibitors within 14 days of Visit 1
  • Use of theophyllines, oral leukotriene inhibitors, long-acting oral beta-agonists, or inhaled long-acting beta-agonists within 48 hours of Visit 1
  • Short-acting oral beta-agonists within 12 hours of Visit 1
  • Use of LABA/ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy within 48 hours of Visit 1 for the LABA component
  • Use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1
  • Use of inhaled short-acting beta-agonists, inhaled short-acting anticholinergics, or inhaled short-acting anticholinergic/short-acting beta-agonist combination products within 6 hours of Visit 1
  • Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer)
  • Oxygen therapy prescribed for greater than 12 hours a day
  • Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators
  • Use of continuous positive airway pressure (CPAP), nocturnal positive pressure or non-invasive positive pressure ventilation (NIPPV), including use for sleep apnea.
  • Acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1
  • A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1
  • Anyone affiliated with investigator site
  • Previous use of GSK573719 or GSK53719/GW642444

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Zadanie krzyżowe
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Tiotropium
18 mcg, inhaled long acting muscarinic antagonist
Lek: Tiotropium
18 mcg once daily
Eksperymentalny: GSK573719
inhaled medication
Lek: GSK573719
125 mcg once daily
Lek: GSK573719
62.5 mcg once daily
Lek: GSK573719
31.25 mcg once daily
Lek: GSK573719
15.6 mcg once daily
Lek: GSK573719
31.25 mcg twice daily
Lek: GSK573719
15.6 mcg twice daily
Komparator placebo: Placebo
inactive/excipients only
Lek: Placebo
once or twice daily

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Final Dose-response Model for Trough Forced Expiratory Volume in One Second (FEV1)
Ramy czasowe: Day 7 and Day 8 of each treatment period (up to Study Day 50)
The trough FEV1 data for both the once-daily (QD) and twice-daily (BID) UMEC doses were included in a parametric analysis in order to evaluate trough FEV1dose response. The Day 8 dataset and a pooled dataset for Day 7 and Day 8 were analyzed separately and reported. The rationale for pooling Day 7 and Day 8 (post-hoc analysis) was to ensure informative interpretation of FEV1 response as a function of dose given the repeated measures for trough FEV1 response within each participant on different days. The fixed-effects parameters of the dose response model include Emax (the maximum predicted FEV1 response), ED50 (potency), and S0 (estimated Baseline FEV1). FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Data for Emax and S0 are reported in this table. mITT=Modified Intent-to-Treat; par.=participants; BL=Baseline.
Day 7 and Day 8 of each treatment period (up to Study Day 50)
Final Dose-response Model for Trough FEV1 for ED50 (Potency) Parameter
Ramy czasowe: Day 7 and Day 8 of each treatment period (up to Study Day 50)
The trough FEV1 data for both the once-daily (QD) and twice-daily (BID) UMEC doses were included in a parametric analysis in order to evaluate dose response. Both a Day 8 dataset and a pooled dataset for Day 7 and Day 8 were analyzed and reported. The rationale for pooling Day 7 and Day 8 (post-hoc analysis) was to ensure informative interpretation of FEV1 response as a function of dose given the repeated measures for trough FEV1 response within each participant on different days. ED50 is defined as the potency and is the dose that yields 50% of Emax (maximum predicted FEV1 response). FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second.
Day 7 and Day 8 of each treatment period (up to Study Day 50)
Final Dose-response Model Parameter β-FEV1MB-S0 for Trough FEV1
Ramy czasowe: Day 7 and Day 8 of each treatment period (up to Study Day 50)
The trough FEV1 data for both the once-daily (QD) and twice-daily (BID) UMEC doses were included in a parametric analysis in order to evaluate dose response. Both a Day 8 dataset and a pooled dataset for Day 7 and Day 8 were analyzed and reported. The rationale for pooling Day 7 and Day 8 (post-hoc analysis) was to ensure informative interpretation of FEV1 response as a function of dose given the repeated measures for trough FEV1 response within each participant on different days. β-FEV1MB-S0 is defined as the covariate (Baseline trough FEV1) effect on the mean Baseline trough FEV1 estimate (S0). FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second.
Day 7 and Day 8 of each treatment period (up to Study Day 50)
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Day 8 of Each Treatment Period
Ramy czasowe: Baseline and Day 8 of each treatment period (up to Study Day 50)
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 8 is defined as the value obtained 24 hours after the morning dose administered on Day 7. Analysis was performed using a mixed model with covariates of mean Baseline, period Baseline, treatment, and period as fixed effects and participant as a random effect. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each particiapant. Change from Baseline for each treatment period is the trough FEV1 at Day 8 minus the Baseline value for that treatment period.
Baseline and Day 8 of each treatment period (up to Study Day 50)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change From Baseline (BL) in Serial FEV1 Over Time on Day 7 of Each Treatment Period
Ramy czasowe: Baseline and Day 7 of each treatment period (TP; up to Study Day 49)
Serial FEV1 for once daily dosing is recorded at the pre-AM dose (AMD; time 0 hour [h]) and at 1, 3, 6, 9, 12,13, 15, 23, and 24 hours after the AMD on Day 7. For twice daily dosing, the 12 h AMD corresponds to the pre-PM dose (PMD), the 13 h AMD corresponds to the 1 h PMD, the 15 h AMD corresponds to the 3 h PMD, the 23 h AMD corresponds to the 11 h PMD, and the 24 h AMD corresponds to the 12 h PMD in this table. Analysis was performed using a mixed model with covariates of mean BL, period BL, treatment, period, time, time by period BL interaction, time by mean BL interaction, and time by treatment interaction as fixed effects and participant as a random effect. BL is the value recorded pre-dose on Day 1 of each TP, mean BLis the mean of the BLs for each participant, and period BL is the difference between the BL and the mean BL in each TP for each participant. Change from BL for each timepoint within a TP is the serial FEV1 measure at that timepoint minus the BL value for that TP.
Baseline and Day 7 of each treatment period (TP; up to Study Day 49)
Change From Baseline (BL) in Weighted Mean FEV1 Over 0 to 24 Hours After the Morning Dosing on Day 7 of Each Treatment Period
Ramy czasowe: Baseline and Day 7 of each treatment period (TP; up to Study Day 49)
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The weighted mean FEV1 was calculated using 0-24 hour post-dose measurements at Day 7 of each treatment period, which included pre-dose and post-dose 1, 3, 6, 9, 12, 13, 15, 23, and 24 hours. Analysis was performed using a mixed model with covariates of mean BL, period BL, treatment, and period as fixed effects and participant as a random effect. BL is the FEV1 value recorded pre-dose on Day 1 of each TP, mean BL is the mean of the BLs for each participant, and period BL is the difference between the BL and the mean BL in each TP for each participant. Change from BL for each TP is the weighted mean FEV1 at Day 7 minus the BL value for that TP.
Baseline and Day 7 of each treatment period (TP; up to Study Day 49)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

GlaxoSmithKline

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 lipca 2011

Zakończenie podstawowe (Rzeczywisty)

1 października 2011

Ukończenie studiów (Rzeczywisty)

27 października 2011

Daty rejestracji na studia

Pierwszy przesłany

9 czerwca 2011

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 czerwca 2011

Pierwszy wysłany (Oszacować)

13 czerwca 2011

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

8 listopada 2017

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

9 października 2017

Ostatnia weryfikacja

1 października 2017

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • 115321

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Badanie danych/dokumentów

  1. Specyfikacja zestawu danych
    Identyfikator informacji: 115321
    Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
  2. Formularz świadomej zgody
    Identyfikator informacji: 115321
    Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
  3. Plan analizy statystycznej
    Identyfikator informacji: 115321
    Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
  4. Protokół badania
    Identyfikator informacji: 115321
    Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
  5. Indywidualny zestaw danych uczestnika
    Identyfikator informacji: 115321
    Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
  6. Raport z badania klinicznego
    Identyfikator informacji: 115321
    Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
  7. Formularz zgłoszenia przypadku z adnotacjami
    Identyfikator informacji: 115321
    Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj